Tenofo-B Tablets 300Mg
300MgRxHepatitis

Tenofo-B

Tenofo-B Tablets 300Mg

Tenofovir Disoproxil

GETZ PHARMA PAKISTAN (PVT) LTD. Box 30 units

Drug Identity

Active Ingredient
Tenofovir Disoproxil
Drug Class
Anti-Infectives
Chemical Class
Adenosine analog
Pharmacological Group
on the basis of mechanism of action
ATC Code
J05AF07
Status
Essential Medicine

What is Tenofo-B?

Uses
Tenofovir is an antiviral medicine that is used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). Tenofov...

How It Works

Chemical Class
Adenosine analog
Pharmacological Group
on the basis of mechanism of action

It is of Semi Synthetic origin and belongs to Adenosine analog. It belongs to Antiviral Agents pharmacological group on the basis of mechanism of action.

How to Take It

1
Adult · PO
300 mg — As recommended.
2
Adult
Scraped Dose
Before you start treatment with tenofovir, your doctor may perform tests to make sure you do not have HIV (if you are being treated for hepatitis B) or hepatitis B (if you are being treated for HIV

Safety Alerts

You should not take tenofovir if you are allergic to it
Do not take tenofovir together with adefovir (Hepsera), or with combination medicines that contain tenofovir (Atripla, Biktarvy , Cimduo, Complera , Descovy, Genvoya, Odefsey, Stribild , Symfi, or Truvada)
Tell your doctor if you have ever had: liver disease (especially hepatitis B if you also have HIV)
HIV (if you are taking tenofovir to treat hepatitis B)
or low bone mineral density

Important Warnings

When treating chronic hepatitis B with tenofovir, monitor liver function tests every 3 months and viral markers for hepatitis B every 3-6 months during treatment (continue monitoring for at least 1 year after discontinuation
recurrent hepatitis may occur on discontinuation), renal or hepatic impairment, hyperphosphataemia
Monitor renal function before treatment, every 4 weeks during first year, then every 3 months
reduce dose or interrupt therapy if serum phosphate or creatinine clearance is decreased
Risk of immune reactivation syndrome in patients with severe immune deficiency within first few weeks or months or starting combination antiretroviral therapy, Risk of osteonecrosis
monitor for signs of joint pain or immobility
Reduced bone mineral density, elderly, Cirrhosis
monitor for hepatic decompensation

Side Effects

Hypophosphataemiareduced bonedensityhyperphosphataemiadizzinessheadacheraised ALT fatiguepancreatitisrashrenal abnormalities lactic acidosisGI disturbance. Rare: Nephrogenic diabetes insipidusproximal renal tubulopathyrenal failure

Drug Interactions

Nephrotoxic drugs
drugs eliminated by active tubular secretion
nucleoside analogues
atazanavir
didanosine
adefovir
tacrolimus. Triple therapy with lamivudine
plus abacavir

Pregnancy & Lactation

Pregnancy
Caution advised, avoid
Lactation
Caution advised, avoid

Storage

Tabs Store in a well closed container, at room temperature, Between 15°C-30°C. Protect from Sunlight, Moisture and Heat.

Price Intelligence

Rs 4,065.9
DVAGO observed price · per pack of 30 · as of 30 July 2026
Rs 135.53 per unit
~43% below the approved ceiling, per unit
DRAP approved ceiling: Rs 7,125.43 (per pack of 30)
0You pay: Rs 135.53/unitRs 237.51/unit
Reg. 057803 · approved 27 Jul, 2026
Prices across sources
DVAGOper pack of 30Rs 4,065.9
DRAPper pack of 30Rs 7,125.43
ServaidRs 3,450

Should you consider an alternative?

Other options containing Tenofovir Disoproxil, and what they are not.

Often Bought Together

For pharma professionalsCompany, market and opportunity intelligence

Company

Prices as of 30 July 2026 · DRAP ceiling as of 30 July 2026 · schema v3-SKU

For medicine intelligence and professional reference only. Not medical advice.